Trials / Completed
CompletedNCT01970215
TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)
A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study of TA-8995 in Patients With Mild Dyslipidaemia, Alone and In Combination With Statin Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 364 (actual)
- Sponsor
- Xention Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy of different doses of TA-8995, a cholesteryl ester transfer protein (CETP) inhibitor, on the elevation of high-density lipoprotein cholesterol (HDL-C) and reduction of low-density lipoprotein cholesterol (LDL-C), alone and in combination with statin therapy. The secondary objectives of this study are to determine the safety and tolerability of TA-8995 in patients with mild dyslipidaemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TA-8995 | |
| DRUG | Atorvastatin | |
| DRUG | Rosuvastatin | |
| DRUG | TA-8995 0mg (placebo) | |
| DRUG | Placebo Statin |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2014-07-01
- Completion
- 2014-07-01
- First posted
- 2013-10-28
- Last updated
- 2014-08-21
Locations
17 sites across 2 countries: Denmark, Netherlands
Source: ClinicalTrials.gov record NCT01970215. Inclusion in this directory is not an endorsement.